Format

Send to

Choose Destination
Rev Med Interne. 2015 May;36(5):328-38. doi: 10.1016/j.revmed.2014.10.364. Epub 2014 Oct 31.

[The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy].

[Article in French]

Author information

1
Département de médecine interne, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
2
Service de réanimation médicale, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
3
Service de médecine interne, CHI Créteil, 94010 Créteil cedex, France.
4
Service d'hématologie biologique, hôpital Lariboisière, 75010 Paris, France; Centre national de référence des microangiopathie thrombotiques, hôpital Saint-Antoine, 75012 Paris, France.
5
Centre national de référence des microangiopathie thrombotiques, hôpital Saint-Antoine, 75012 Paris, France; Unité Inserm U1009, institut Gustave-Roussy, 94805 Villejuif cedex, France; Service d'hématologie, hôpital Saint-Antoine, 75012 Paris, France.
6
Département de médecine interne, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Service de réanimation médicale, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France; Centre national de référence des microangiopathie thrombotiques, hôpital Saint-Antoine, 75012 Paris, France. Electronic address: ygal.benhamou@chu-rouen.fr.

Abstract

Thrombotic microangiopathies (TMA) define a syndrome characterized by the association of microangiopathic haemolytic anaemia with schistocytes, peripheral thrombocytopenia, and organ injury of variable severity. Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uremic syndrome (HUS) are the main forms of TMA. Recent advances in the pathophysiology of those two diseases, which include in HUS the identification of a deregulation of the alternative complement pathway, and in TTP a severe deficiency in ADAMTS-13, allowed to develop specific, pathophysiology-based therapies. Therefore, rituximab and eculizumab tends to be increasingly used, and there is an urgent need to define consensual modes of administration at the international level, as well as common definitions of response evaluation and follow-up explorations.

KEYWORDS:

Eculizumab; Haemolytic and uremic syndrome; Microangiopathie thrombotique; Purpura thrombotique thrombocytopénique; Rituximab; Syndrome hémolytique et urémique; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; Éculizumab

PMID:
25547956
DOI:
10.1016/j.revmed.2014.10.364
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center